Abstract: A hair mask composition, comprising, about 50-60% of distilled water to comprise an aqueous solution, an amount of clay sufficient to produce a paste, an amount of a moisturizer component effective for adding moisture to hair strands without leaving a greasy film on hair after shampoo, and an amount of plant protein which also acts as a strengthening hair agent.

Abstract: The present invention relates to a composition for topical application consisting of an aqueous phase and an oily phase, which are separate and transparent, comprising at least one surfactant that is liquid at room temperature and at atmospheric pressure, with an HLB<8 and chosen from fatty acid esters of sugar and alkyl polyglucosides, at least one branched alkane comprising from 8 to 18 carbon atoms, and from 0 to 4% by weight of silicone oils relative to the total weight of the composition. The composition according to the invention makes it possible to obtain, after shaking, an emulsion that rapidly separates again into two transparent phases, having a perfectly sharp interface and with no appearance of droplets that remain attached to the walls of the transparent container. The composition in accordance with the invention has the same makeup-removing efficacy and better sensory properties, and in particular it leaves less greasy residue on the skin.

Abstract: An oxidative hair dye composition includes an alkaline agent and an oxidant. The oxidative hair dye composition further includes (A) ?-naphthol in a content of 0.005 to 0.45% by mass, (B) at least one oily component selected from a higher alcohol, an ester, and a wax that are in a liquid state at 25° C., and (C) a nonionic surfactant having a polyoxyethylene chain having a number of moles of added ethylene oxide of 20 or more.

Abstract: The present invention describes cosmetic nanotechnology, comprising polymeric nanoparticles containing oil and UV filter, photoprotective compositions comprising polymeric nanoparticles described herein, methods of prevention of diseases of the skin, and processes for the preparation of the polymeric nanoparticles described herein.

Abstract: The present invention relates to a composition for promoting hair growth or preventing hair loss and, specifically, to a composition, which has excellent stability for skin and no side effects, promotes hair growth, prevents hair loss through the delay of hair loss, and has an excellent hair growth effect.

Abstract: A hair fixative composition includes at least one carboxylated cellulose ether based polyglucose polymer, an alcohol based solvent system, and a cosmetically acceptable additive, wherein the polyglucose polymer is soluble in the alcohol based solvent system. The polyglucose polymer is obtained by reacting at least one cellulose ether with at least one anhydride.

Abstract: A hair cosmetic composition includes an alkaline agent and an oxidant, and is constituted as a hair dye or a hair bleaching/dye removing agent. The hair cosmetic composition further includes (A) a cellulose derivative and (B) a polyethylene glycol having a number average molecular weight of 2,000 or less. The mass ratio of the content of the (B) component to the content of the (A) component is 1 to 50.

Abstract: The present invention relates to compositions containing polymeric, ionic compounds comprising imidazolium groups. In particular, it relates to the use of polymeric, ionic compounds comprising imidazolium groups in personal care compositions and/or in biocide compositions.

Abstract: The invention relates to a composition containing between 0.1 and 30 wt.-% copolyamide (COPA) and between 70 and 99.9 wt.-% of a medium acceptable for cosmetic, perfume and/or pharmaceutical use. In particular, the invention relates to a method for incorporating a copolyamide into a cosmetic, perfume and/or pharmaceutical medium. The invention also relates to the use of a copolyamide (COPA) for the production of a cosmetic, pharmaceutical or perfume product, said COPA being incorporated in the form of a composition in accordance with the invention.

Abstract: The present invention relates to a novel sebum secretion inhibitor and use thereof for the production of cosmetic and pharmaceutical, notably dermatological, compositions, intended for preventing and/or reducing the secretion of sebum and notably of squalene.

Abstract: Personal lubricants containing royal jelly, a glow powder or xylitol are provided.

Abstract: The present invention relates to a vaginal suppository comprising an inert vehicle and lactic acid or a salt thereof for the treatment and/or prophylaxis of disorders in the urogenital tract. It also relates to the use of such a suppository for the production of a medicament for the treatment and/or prophylaxis of disorders in the urogenital tract as well as to a method for the treatment and/or prophylaxis of disorders in the urogenital tract.

Abstract: A solid dosage form of meloxicam containing an acid and sugars or polyalcohols or a mixture thereof.

Abstract: Disclosed are compositions containing chemical constituents from plants, uses of these compositions and methods for making them. In various embodiments, the present invention relates to an improved modes of administration of herbal remedies.

Abstract: Human sperm is mobile only in a slightly acidic environment which is the normal state of the human vagina. Soap is a very basic material; introduction of a small amount of soap into the vagina before intercourse will raise the pH, a condition which causes the sperm to coagulate into a ball, that exits the vagina upon simply rinsing with water. The present invention is a composition of soap, water, and other natural materials that can be used as a vaginal suppository.

Abstract: Apixaban liquid formulation is provided. Also provided is a method of administering an apixaban liquid formulation.

Abstract: Provided are compositions and methods for producing water-soluble powders that contain additives such as essential fatty acids, including omega-3 fatty acids, omega-6 fatty acids, conjugated fatty acids, and other fatty acids; phytochemicals, including phytosterols; other oils; and coenzymes, including coenzyme Q10, and other oil-based additives.

Abstract: The present invention discloses an improved nanoemulsion comprising a uniform and discrete range of very small particle nano-sized diameters. This uniformity results in improved bioavailability of incorporated compounds (i.e., pharmaceuticals or nutraceuticals) as reflected in various pharmacokinetic parameters including, but not limited to, decreased Tmax, increased CmaX3 and increased AUC. The improved method of making these uniform nanoemulsions utilizes microfluidization which differs in both process and mechanics when compared to conventional milling and grinding techniques used to generate nanoparticulate compositions. Further, the improvement results, in part, from a novel step of mixing a substantially soluble compound into a heated dispersion medium. This is unlike current nanoparticulate composition methods that mix an insoluble compound with an unheated dispersion medium. Further, these nanoemulsions are observed to be bacterial-resistant and stable to extremes in both temperature and pH changes.

Abstract: The present invention is directed to a method for treating cancer intraperitoneally in a subject. The method comprises administering to said subject in need thereof an anti-cancer agent encapsulated in nanoparticles wherein nanoparticles are characterized to slowly release anti-cancer agent in a timely fashion that allows efficient killing of tumor cells. The nanoparticles described herein are characterized to slowly release anti-cancer agent at a rate of 30% or less per 24 hours based on in vitro drug dissolution study.

Abstract: A method of preparing a lyophilized powder for injection, including: (1) weighing and mixing aloe powder and Panax pseudo-ginseng powder to yield an active pharmaceutical ingredient, and mixing the active pharmaceutical ingredient and distilled water to yield a mixed aqueous solution; (2) stiffing the mixed aqueous solution to enable the aloe power and the Panax pseudo-ginseng powder to be completely dissolved, and then allowing the mixed aqueous solution to stand; (3) collecting, filtering, and clarifying a supernate obtained in (2); (4) adding hydrochloric acid to a filtrate obtained in (3) to adjust the pH value of the filtrate, heating and sterilizing the filtrate, and then naturally cooling the filtrate, to yield a cooled liquid; (5) adding hydrochloric acid to the cooled liquid to adjust the pH value of the cooled liquid, filtering the cooled liquid and collecting a pharmaceutical solution; and (6) packaging and lyophilizing the pharmaceutical solution.

Abstract: The present invention relates to a cellulose powder usable for a satisfactory orally disintegrating tablet having excellent compression moldability and well-balanced tablet moldability and disintegration properties, which can obtain excellent ingestion feel without feeling roughness and dryness in the oral cavity, and more particularly to a cellulose powder with an average polymerization degree of 150 to 450, an average particle diameter of not less than 10 ?m but less than 100 ?m, and a primary particle ratio of 50% or more.

Abstract: Methods and compositions are provided which comprise effective amounts of one or more analgesics, such as hydrocodone or acetaminophen, and an antiemetic, such as promethazine, to treat or prevent pain in a subject, and to reduce or prevent an adverse effect associated with the analgesics.

Abstract: A novel gelatin comprising dosage form article for oral administration and for containing therein a fill composition, the fill composition comprising one or more active materials capable of reacting with gelatin, and optionally one or more excipient materials, wherein the dosage form is made of a gelatin material and one or more plasticizers, the gelatin material having a mean molecular weight of less than about 130,000 g/mol and a low microgel content, wherein the fraction of microgel is of less than about 10% of the total number of gelatin chains of the gelatin material.

Abstract: The present invention relates to compositions, devices and methods of delayed and sustained release of energy molecules for brain function to treat nocturnal hypoglycemia. The composition comprises an energy molecule required for human brain function; wherein the release of the energy molecule is delayed and then sustained over a period of time. The device is a transdermal delivery device comprising a reservoir layer containing the composition and a skin permeation enhancer formulation, an adhesive layer, a backing layer and a release liner. The method comprises administering the composition either orally or through the transdermal delivery device to a subject in need thereof immediately prior to going to sleep.

Abstract: The present invention provides antigen-specific, tolerance-inducing microparticles for the targeted delivery of therapeutic agents to immune cells. In addition, the present invention allows for sustained release of therapeutic agents for a prolonged period of time. Also provided are therapeutic uses of the present invention for the prevention and/or treatment of immune diseases and autoimmune disorders. In a specific embodiment, the present invention provides treatment for type 1 diabetes.

Abstract: A method for delivering a therapeutic agent to a subject from a transdermal delivery system is described, where the therapeutic agent (i) has a half-life in the blood when delivered orally of greater than about 48 hours and (ii) is for the treatment of a chronic condition. The transdermal delivery system achieves transdermal delivery of the therapeutic agent at steady state that is bioequivalent to administration of the therapeutic agent orally, wherein bioequivalency is established by (a) a 90% confidence interval of the relative mean Cmax and AUC of the therapeutic agent administered from the transdermal delivery system and via oral delivery between 0.70 and 1.43 or between 0.80 and 1.25, or (b) a 90% confidence interval of the ratios for AUC and Cmax of the therapeutic agent administered from the transdermal delivery system and via oral delivery between 0.70 and 1.43 or between 0.80 and 1.25.

Abstract: The present invention provides cannabinoid type 2 (CB2) receptor inverse agonists for treating or ameliorating psychiatric disorders. The present invention further provides pharmaceutical compositions comprising 4?-O-methylhonokiol for treating Attention Deficit Hyperactivity Disorder (ADHD) and Tourette's syndrome.

Abstract: The present invention relates to pharmaceutical composition of Cinacalcet or a pharmaceutically acceptable salt thereof comprising diluents, binders and lubricants, wherein said composition is substantially free of disintegrant. It further relates to process for preparing such compositions.

Abstract: The subject invention provides materials and methods for reducing ocular infections in subjects. The materials and methods utilize chlorhexidine, which has been found to be unexpectedly non-toxic to humans and other animals in low concentrations. The lack of toxicity facilitates the use of chlorhexidine in contexts that were not previously thought possible.

Abstract: Provided is a composition for alleviating nephrotoxicity caused by an immunosuppressive drug, including metformin, and a composition for preventing or treating an immune disease, including the same. Further, the composition provided can be useful in improving a treatment effect on diseases requiring immunosuppression by effectively alleviating a decline in renal function caused due to side effects of conventional immunosuppressive drugs, and can also be useful in preventing or treating organ transplant rejection, autoimmune diseases, inflammatory diseases and the like since various methods of co-administering a conventional immunosuppressive drug and metformin are suggested to reduce nephrotoxic side effects of conventional immunosuppressive drugs and maximize immunosuppressive or immunomodulatory effects.

Abstract: The present invention relates to method of treatment of hepatitis C using bufexamac or a derivative thereof. The methods of the present invention can be used in patients with hepatitis C administering bufexamac or a derivative thereof in combination with one or more anti-hepatitis C drugs.

Abstract: Methods are provided for preventing, inhibiting, or treating intimal hyperplasia in a patient who has undergone a coronary bypass procedure that include providing a solution comprising DCA added to water; and administering the solution orally to a patient to prevent, inhibit, or treat intimal hyperplasia.

Abstract: A method of treatment for third spacing is provided. The method includes identifying an adverse factor, which includes conditions causing an increase in vascular permeability resulting in third spacing. The method also includes diagnosing the patient with third spacing, which can include third spacing of fluids, materials, or both. The patient is treated with a therapeutically effective amount of a non-increased vascular permeability modifier loop diuretic, such as a non-sulfonamide loop diuretic like ethacrynic acid or ethacrynate sodium.

Abstract: This disclosure provides generally for antimicrobial compositions and methods of use comprising an anthocyanin, an anthocyanidin or metabolites thereof. Methods for promoting healing of a wound using these compositions are also disclosed. These compositions have broad spectrum antimicrobial activity and are safe for human and animal uses. Further, these compositions are safe for medical uses and industrial uses as antiseptic preparations to reduce or prevent microbial growth, including killing bacterial biofilms.

Abstract: The present invention relates to compounds comprising the general formula (I), in which R1 and R2, which may be identical or different, are selected from the group comprising —H or a linear or branched alkyl group having from 1 to 6 carbon atoms or together form an aromatic or aliphatic ring with 5 or 6 atoms; Y and Z, which may be identical or different, are selected from the group comprising —H, —OH, —COOH, —OR3, —CH(OR3)COOH, in which R3 is selected from H, phenyl, benzyl, —CF3 or —CF2CF3, vinyl, allyl and a linear or branched alkyl group having from 1 to 6 carbon atoms.

Abstract: A method for reducing muscle damage and/or oxidative stress in active mammals as disclosed. In one embodiment, the mammals are administered a carnitine supplement. The L-carnitine supplement may be administered without any other pharmaceutical or drug products. After physical activity the L-carnitine supplement can lower myoglobin, TBARS, and creatine kinase in the bloodstream.

Abstract: The present application relates to combination treatments for bacterial infections. For example, the application relates to the use of one or more ?-lactam antibiotics and one or more compounds of Formula I: (I) for treatment of a metallo-B-lactamase-expressing bacterial infection or a disease, disorder or condition arising from a metallo-B-lactamase-expressing bacterial infection.

Abstract: The subject invention relates to a variety of formulations of bipolar trans carotenoids including pharmaceutical compositions for oral delivery of a bipolar trans carotenoid comprising i) a bipolar trans carotenoid, ii) a cyclodextrin, and iii) a coating. The invention also relates to preparation of such formulations and their uses.

Abstract: A method and composition for extending the lifespan of an individual and delaying the onset of age-related disease is provided. The method includes the administration of an effective dose of oxaloacetate, wherein the oxaloacetate acts to mimic the cellular conditions obtained under caloric restriction to provide similar benefits. The invention further includes methods and compositions for reducing the incidence or treatment of cancer. Compositions and methods for reducing body fat by administering an effective amount of oxaloacetate are likewise provided. Compositions for DNA repair in UV damaged cells is provided are also provided. Similarly, a method for treating a hang-over comprising administering an effective amount of oxaloacetate is disclosed.

Abstract: In various embodiments, the present invention provides methods of reducing the risk of a cardiovascular event in a subject on statin therapy and, in particular, a method of reducing the risk of a cardiovascular event in a subject on statin therapy having a fasting baseline triglyceride level of about 135 mg/dL to about 500 mg/dL, and administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of eicosapentaenoic acid ethyl ester or a derivative thereof.

Abstract: Method for treating melanoma is provided.

Abstract: An ophthalmic lens or an intraocular lens releasing anthocyanin for the benefit of a user's eyes includes a matrix and anthocyanin dispersed in the matrix. An ophthalmic lens package includes a lens protection solution and the ophthalmic lens, the ophthalmic lens is immersed in the lens protection solution.

Abstract: A method of preparing liposomes, liposome compositions formed by the process, and methods of using the liposome composition are provided herein.

Abstract: Provided in the present invention are uses of duloxetine hydrochloride in preparing a pharmaceutical composition for treatment of cancer.

Abstract: The present invention relates in part a to multiparticulate sprinkle dosage form comprising duloxetine or a pharmaceutically acceptable salt thereof, having higher acid resistance as compared to commercially available delayed release formulations. It further relates to various methods of administering the said multiparticulate sprinkle dosage forms.

Abstract: A method for treating cancer is described using combination therapies comprising the use of hyperbaric oxygen with histone deacetylase inhibitors, with and without glycolytic therapies. The patient is subjected to a hyperbaric environment of substantially pure oxygen. A predetermined dose of one or more HDACI substances is administered to the patient. In addition, glycolitic inhibitors may also be administered. Dosages, pressures, and durations are selected as described herein to have a therapeutic effect on the patient.

Abstract: The present disclosure relates to: (a) methods of using stabilized pharmaceutical dosage forms comprising atrasentan, or a pharmaceutically acceptable salt thereof, and, optionally, another therapeutic agent to treat type 2 diabetes, microalbuminuria or macroalbuminuria; and (b) methods for the preparation of such pharmaceutical dosage forms.

Abstract: The invention provides methods of treatment of a progressive bone disease, such as osteoporosis, Paget's Disease, multiple myeloma, or hyperparathyroidism, comprising administration of an effective amount of a non-agonist PPARG modulator to a patient afflicted with the disease.

Abstract: The present invention addresses the problem of providing a novel therapeutic agent for keratoconjunctive disorders. As a means for solving the problem, a therapeutic agent for keratoconjunctive disorders which contains a RAR? agonist as an active ingredient is provided. The therapeutic agent exhibits an excellent ameliorating effect in a keratoconjunctive disorder model, and is therefore useful as a therapeutic agent for keratoconjunctive disorders such as corneal ulcer, corneal epithelial abrasion, keratitis, dry eye, conjunctivitis, chronic superficial keratitis, corneal erosion, persistent corneal disorders, superficial punctate keratopathy, corneal epithelial defects, conjunctival epithelial defects, keratoconjunctivitis sicca, superior limbic keratoconjunctivitis, filamentary keratoconjunctivitis, infectious keratitis, noninfectious keratitis, infectious conjunctivitis and noninfectious conjunctivitis.

Abstract: The presently disclosed subject matter relates to pharmaceutical compositions comprising dexmedetomidine or a pharmaceutically acceptable salt thereof wherein the composition is formulated as a liquid for parenteral administration to a subject, and wherein the composition is disposed within a sealed container as a premixture. The pharmaceutical compositions can be used, for example, in perioperative care of a patient or for sedation.